|
Obesity
|
0.520 |
AlteredExpression
|
disease |
BEFREE |
SC AT GPX3 expression is significantly higher in lean compared to obese as well as in insulin-sensitive compared insulin-resistant individuals with obesity.
|
30537708 |
2018 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
CTD_human |
Perturbation of eight out of the nine genes, with Gas7, Me1 and Gpx3 being newly confirmed, resulted in significant changes in obesity-related traits.
|
19270708 |
2009 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
RGD |
High fat feeding and dietary L-arginine supplementation differentially regulate gene expression in rat white adipose tissue.
|
19212806 |
2009 |
|
Obesity
|
0.520 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that suppression of GPx3 expression in the adipose tissue of obese subjects might constitute a vicious cycle to expand local reactive oxygen species accumulation in adipose tissue potentially into systemic oxidative stress and obesity-related metabolic complications.
|
18562625 |
2008 |
|
Obesity
|
0.520 |
Biomarker
|
disease |
CTD_human |
Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue.
|
11328671 |
2001 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
GPx3 is an extracellular glutathione peroxidase with reported dichotomous roles in cancer.
|
30509602 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of the GPx3 promoter and suppression of GPx3 expression are associated with inflammation, tumorigenesis, and response to chemotherapy in various types of cancer.
|
30898707 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
SROC analysis showed for GPX3 methylation was a promising biomarker for cancer risk (AUC = 0.89, pooled sensitivity = 0.93, pooled specificity = 0.54, NLR = 0.15, PLR = 2.05, DOR = 17.32).
|
31085009 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High GPx3 expression was associated with poorer overall patient survival and increased tumor stage.
|
30509602 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, our study indicates that GPX3 methylation is associated with cancer and has the potential to become a broad-spectrum tumor screening marker and has a value in predicting tumor lymph node metastasis.
|
31085009 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
GPX3 suppresses tumor migration and invasion via the FAK/AKT pathway in esophageal squamous cell carcinoma.
|
30018730 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To further elucidate the mechanism(s) underlying GPx3-medited suppression of tumor proliferation, we next examined the effect of GPx3-mediated redox signaling on the ROS-MKP3-extracellular signal-regulated kinase (Erk)-NF-κB-cyclin B1 pathway and found that GPx3 strongly suppressed activation of the Erk-NF-κB-cyclin B1 signaling cascade by protecting MKP3 (an Erk-specific phosphatase) from the effects of ROS.
|
30260967 |
2018 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The plasma glutathione peroxidase (GPX1) levels in gallstone patients operated with laparoscopic cholecystectomy (LC) or minicholecystectomy (MC) versus cancer patients is unknown.
|
29187474 |
2017 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Epigenetic inactivation of GPX3 has been identified in various cancers including leukemia.
|
27891827 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In vivo, GPX3 methylation predicts tumor xenograft sensitivity to platinum with regression of GPX3 knockdown xenografts with platinum treatment but continued growth of GPX3 wild type xenografts in the presence of platinum.
|
27918237 |
2017 |
|
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
As a crucial antioxidant enzyme, glutathione peroxidase 3 (GPX3) has been found to be frequently repressed in many cancers due to promoter hypermethylation and is known as a possible tumor suppressor gene.
|
27600457 |
2016 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This result prompted us to investigate whether GPx3 expression is regulated by the glucocorticoid receptor (GR), which is implicated in tumor response to chemotherapy.
|
27484907 |
2016 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The changes in activity of GPX1, GPX2, and GPX3 isoforms may be associated with the development of cancers, for example, prostate cancer or even colon cancer.
|
26682223 |
2015 |
|
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
GPX3 promoter methylation was detected in 46 of 60 (76.7%) tumors, while no GPX3 gene promoter methylation was observed in the matched non-cancerous specimens.
|
25445749 |
2015 |
|
Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
GPX3 was methylated in 46.8% (44 of 94) of PTC and methylation of GPX3 was associated with tumor size (P<0.05) and regional lymph node metastasis (P<0.01) significantly.
|
25929866 |
2015 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In our study, GPX3 methylation and down-regulation were detected in 5 out of 6 ccRCC cell lines and the GPX3 mRNA and protein expression level in ccRCC tumors was significantly lower than in adjacent non-malignant renal tissues (p<0.0001).
|
25970749 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the role of GPX3 has been studied in different cancer types, its role in breast cancer and its epigenetic regulation have not yet been investigated.
|
24790704 |
2014 |
|
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Downregulation of GPX3 due to its promoter hypermethylation has been documented in several different types of cancer, indicating that GPX3 functions as a possible tumor suppressor.
|
24788695 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The methylation of THBS1 and GPX3 was not significantly different between the types of tumors, normal sample, the presence of H. pylori, or clinicopathological variables studied (P > 0.05).
|
24014049 |
2014 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
GPx3 could be delivered by hiPSC-MSCs into the tumor and exhibited tumor suppressive activity in vivo.
|
25333265 |
2014 |